Adults with migraine with aura were found at significantly greater risk for AF and those younger than age 55 years were particularly vulnerable, write Mayo Clinic investigators.
The dextromethorphan HBr-bupropion HCI combination uses the first new oral MOA in 6 decades and is labeled to improve depressive symptoms starting at 1 week.
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Henry Mahncke, PhD, on the impact of cannabis on cognitive health.
If the atogepant label is expanded, the drug will be the only gepant approved for the broad indication of prevention of both episodic and chronic migraine.
Henry Mahncke, PhD, explains why lifestyle interventions, such as diet and exercise, could be prescribed down the line to improve brain health.
Treatment with intranasal insulin improved executive function and verbal memory, as well as other measures, in participants with and without type 2 diabetes.
Yale headache specialist Christopher Gottschalk, MD, talks about the opportunities to make a marked difference in the quality of patients' lives.
US patients diagnosed with migraine: 40 million. US headache specialists: 600. Primary care is the answer, according to Christopher Gottschalk, MD.
"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with headache specialist Peter McAllister, MD.
Gottschalk says CGRP inhibitors have made "...a life-changing transformation in how we think about and the kind of expectations we set for migraine treatment."